Although we are now learning that the useful relationship among MMP-1 expression and well-known clinic/pathologic-prognostic factors (such as Ki-67, HER-2, Bcl-2, tumor grade and cancer subtypes) may help us to enhance and increase the clinically useful prognostic factors, what we need are future biochemical, molecular and clinical studies assessing many different biomarkers head-to-head, because MMP-1 analysis alone is no longer the way to go. Here, ERBB2 is linked to cancer.